Agenus saw the highest growth of 3.99% in patent filings and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and grants by 0.19%. GlobalData’s DataBook provides a comprehensive analysis of Agenus‘s patent filings and grants. Buy the databook here.
Agenus has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 31% filings and 75% grants. The World Intellectual Property Organization(WIPO), United States(US), Chile(CL), and China(CN) patent Office are among the top ten patent offices where Agenus is filings its patents. Among the top granted patent authorities, Agenus has 75% of its grants in United States(US) and 25% in China(CN).
Roche could be the strongest competitor for Agenus
Patents related to climate change and rare diseases lead Agenus's portfolio
Agenus has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 67% of patents were filed and no patents were granted in Q2 2024.
Shock related patents lead Agenus portfolio followed by cervical cancer, and pancreatic cancer
Agenus has highest number of patents in shock followed by cervical cancer, pancreatic cancer, viral infections, and human papillomavirus infections. For shock, nearly 20% of patents were filed and 12% of patents were granted in Q2 2024.
For comprehensive analysis of Agenus's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.